{"id":24845,"date":"2024-06-17T14:00:00","date_gmt":"2024-06-17T12:00:00","guid":{"rendered":"https:\/\/ggba.swiss\/?p=24845"},"modified":"2024-06-17T11:59:03","modified_gmt":"2024-06-17T09:59:03","slug":"sensars-obtient-eur-11-million-pour-faire-avancer-sa-technologie-de-neuromodulation","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/sensars-obtient-eur-11-million-pour-faire-avancer-sa-technologie-de-neuromodulation\/","title":{"rendered":"SensArs obtient EUR 1,1 million pour faire avancer sa technologie de neuromodulation"},"content":{"rendered":"\n

Fond\u00e9e en 2014 en tant que spin-off de l’EPFL, SensArs est sp\u00e9cialis\u00e9e dans la technologie de neuromodulation visant \u00e0 soulager la douleur chronique et la perte sensorielle. L’approche innovante de l’entreprise combine des capteurs portables avanc\u00e9s avec des logiciels pilot\u00e9s par l’IA pour cr\u00e9er des plans de traitement personnalis\u00e9s pour les patients, am\u00e9liorant ainsi de mani\u00e8re significative leur qualit\u00e9 de vie.<\/p>\n\n\n\n

SensArs<\/a> a re\u00e7u une bourse de EUR 500’000 du programme Eurostars pour son dernier projet, SENSOLE. Ce projet vise \u00e0 cr\u00e9er le premier syst\u00e8me au monde capable de surveiller et de traiter les troubles de la marche et la douleur chez les patients souffrant d’une perte sensorielle induite par une neuropathie de la jambe. SENSOLE comporte des capteurs portables qui fournissent des donn\u00e9es d\u00e9taill\u00e9es sur les mouvements de la jambe et les points de pression dans diff\u00e9rentes zones du pied. Associ\u00e9 \u00e0 un neurostimulateur, SENSOLE att\u00e9nue les complications de la neuropathie en r\u00e9tablissant un retour d’information sensoriel en temps r\u00e9el. Le syst\u00e8me utilise un logiciel pilot\u00e9 par l’IA pour offrir des conseils de traitement personnalis\u00e9s bas\u00e9s sur les donn\u00e9es individuelles du patient.<\/p>\n\n\n\n

Parall\u00e8lement, SensArs Germany, la filiale allemande de SensArs, a obtenu une bourse de EUR 600’000 du minist\u00e8re f\u00e9d\u00e9ral allemand de l’\u00e9ducation et de la recherche (BMBF). Cette bourse soutiendra des initiatives de recherche visant \u00e0 tester SENSY, le neurostimulateur implantable brevet\u00e9 de SensArs, chez des personnes amput\u00e9es. En collaboration avec l’Universit\u00e9 de Heidelberg, cette initiative \u00e9valuera l’efficacit\u00e9 de SENSY dans la gestion de la douleur chez les amput\u00e9s, faisant ainsi progresser la mission de SensArs qui consiste \u00e0 innover dans le domaine de la neuromodulation.<\/p>\n\n\n\n

Transformer le paysage de la neuromodulation<\/h4>\n\n\n\n

En outre, SensArs a obtenu un investissement de pr\u00e9-amor\u00e7age de la part de HTH<\/a>, un investisseur italien en capital-risque qui se consacre \u00e0 l’am\u00e9lioration de la sant\u00e9 humaine. \u00ab Nous sommes tr\u00e8s heureux de recevoir ces investissements et ces bourses, qui soulignent la confiance dans nos technologies innovantes et l’impact potentiel qu’elles peuvent avoir sur la vie des patients \u00bb, a d\u00e9clar\u00e9 Francesco Petrini, CEO de SensArs. \u00ab Avec ces ressources, nous sommes bien positionn\u00e9s pour acc\u00e9l\u00e9rer nos efforts de recherche et de d\u00e9veloppement, ce qui nous rapproche de notre objectif de transformer le paysage de la neuromodulation et d’offrir de l’espoir \u00e0 des millions de personnes souffrant de douleurs chroniques et de perte sensorielle. \u00bb<\/p>\n\n\n\n

Guy Siman, COO de SensArs, a ajout\u00e9 : \u00ab Ces avanc\u00e9es marquent des \u00e9tapes significatives dans notre parcours vers l’am\u00e9lioration de l’efficacit\u00e9 et de l’accessibilit\u00e9 des traitements de neuromodulation. Nous nous engageons \u00e0 tirer parti de ces ressources pour stimuler l’innovation et fournir des solutions tangibles qui r\u00e9pondent aux besoins non satisfaits des patients dans le monde entier.\u00a0\u00bb<\/p>\n","protected":false},"excerpt":{"rendered":"

SensArs, une spin-off de l’EPFL sp\u00e9cialis\u00e9e dans la technologie de neuromodulation pour le traitement de la douleur chronique et de la perte sensorielle, a obtenu un investissement de pr\u00e9-amor\u00e7age de HTH et deux bourses d’une valeur de EUR 1,1 million.<\/p>\n","protected":false},"author":6,"featured_media":24842,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1148,1163,1239,1141],"class_list":["post-24845","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-financing-fr-2","tag-medtech-fr-2","tag-neuroscience-fr-2","tag-personalized-medicine-fr-2"],"acf":[],"yoast_head":"\nSensArs l\u00e8ve EUR 1,1M pour sa technologie de neuromodulation<\/title>\n<meta name=\"description\" content=\"SensArs, une spin-off de l'EPFL a obtenu un investissement de pr\u00e9-amor\u00e7age de HTH et deux bourses d'une valeur de EUR 1,1 million.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SensArs l\u00e8ve EUR 1,1M pour sa technologie de neuromodulation\" \/>\n<meta property=\"og:description\" content=\"SensArs, une spin-off de l'EPFL a obtenu un investissement de pr\u00e9-amor\u00e7age de HTH et deux bourses d'une valeur de EUR 1,1 million.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-17T12:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/Sensars-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"SensArs obtient EUR 1,1 million pour faire avancer sa technologie de neuromodulation\",\"datePublished\":\"2024-06-17T12:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/\"},\"wordCount\":502,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/Sensars-1180x811-1.jpg\",\"keywords\":[\"Financing\",\"Medtech\",\"Neuroscience\",\"Personalized Medicine\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/\",\"url\":\"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/\",\"name\":\"SensArs l\u00e8ve EUR 1,1M pour sa technologie de neuromodulation\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/Sensars-1180x811-1.jpg\",\"datePublished\":\"2024-06-17T12:00:00+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"SensArs, une spin-off de l'EPFL a obtenu un investissement de pr\u00e9-amor\u00e7age de HTH et deux bourses d'une valeur de EUR 1,1 million.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/Sensars-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/Sensars-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"Francesco Petrini, cofondateur et CEO de SensArs, avec le produit innovant SENSY de la soci\u00e9t\u00e9, une solution avanc\u00e9e pour le soulagement de la douleur chronique. | \u00a9 SensArs\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SensArs obtient EUR 1,1 million pour faire avancer sa technologie de neuromodulation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SensArs l\u00e8ve EUR 1,1M pour sa technologie de neuromodulation","description":"SensArs, une spin-off de l'EPFL a obtenu un investissement de pr\u00e9-amor\u00e7age de HTH et deux bourses d'une valeur de EUR 1,1 million.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/","og_locale":"fr_FR","og_type":"article","og_title":"SensArs l\u00e8ve EUR 1,1M pour sa technologie de neuromodulation","og_description":"SensArs, une spin-off de l'EPFL a obtenu un investissement de pr\u00e9-amor\u00e7age de HTH et deux bourses d'une valeur de EUR 1,1 million.","og_url":"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-06-17T12:00:00+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/Sensars-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"SensArs obtient EUR 1,1 million pour faire avancer sa technologie de neuromodulation","datePublished":"2024-06-17T12:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/"},"wordCount":502,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/Sensars-1180x811-1.jpg","keywords":["Financing","Medtech","Neuroscience","Personalized Medicine"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/","url":"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/","name":"SensArs l\u00e8ve EUR 1,1M pour sa technologie de neuromodulation","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/Sensars-1180x811-1.jpg","datePublished":"2024-06-17T12:00:00+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"SensArs, une spin-off de l'EPFL a obtenu un investissement de pr\u00e9-amor\u00e7age de HTH et deux bourses d'une valeur de EUR 1,1 million.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/Sensars-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/06\/Sensars-1180x811-1.jpg","width":1180,"height":811,"caption":"Francesco Petrini, cofondateur et CEO de SensArs, avec le produit innovant SENSY de la soci\u00e9t\u00e9, une solution avanc\u00e9e pour le soulagement de la douleur chronique. | \u00a9 SensArs"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/sensars-secures-eur-1-1-million-to-advance-neuromodulation-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"SensArs obtient EUR 1,1 million pour faire avancer sa technologie de neuromodulation"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/24845","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=24845"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/24845\/revisions"}],"predecessor-version":[{"id":24847,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/24845\/revisions\/24847"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/24842"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=24845"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=24845"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=24845"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}